Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: Quantitative analysis in seven strains of Mus musculus

Brain Research

Volumn 828, Issue 1-2, 1999, Pages 91-103

  Hamre, Kristin ^a   Tharp, Ruby ^a   Poon, Kenneth ^a   Xiong, Xiaoping ^a   Smeyne, Richard J ^a  

^a St Jude Children's Research Institute   (United States)

Author keywords

Basal ganglia; Gender; Neurogenetics; Neurotoxin; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BASAL GANGLION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; GENETIC ANALYSIS; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; CELL COUNT; DISEASE SUSCEPTIBILITY; DOPAMINE AGENTS; FEMALE; GENES, DOMINANT; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MPTP POISONING; NEURONS; PARKINSON DISEASE, SECONDARY; SEX FACTORS; SPECIES SPECIFICITY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0033562891     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01273-1     Document Type: Article

References (84)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94:1946;239-247.
2. Akhmedova S.N., Pushnova E.A., Yakimovsky A.F., Avtonomov V.V., Schwartz E.I. Frequency of a specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson disease. Biochem. Moll. Med. 54:1995;88-90.
3. Ali S.F., David S.N., Newport G.D. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology. 14:1993;29-34.
4. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:1994;27-34.
5. Andersen J.K., Frim D.M., Isacson O., Beal M.F., Breakefield X.O. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res. 656:1994;108-114.
6. Andrews A.M., Ladenheim B., Epstein C.J., Cadet J.L., Murphy D.L. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2′-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Mol. Pharmacol. 50:1996;1511-1519.
7. Andrews A.M., Murphy D.L. 2′-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. J. Pharmacol. Exp. Ther. 267:1993;1432-1439.
8. Andrews A.M., Murphy D.L. Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2′-NH2-MPTP): a comparative study with 2′-CH3-MPTP and MPTP. J. Neurochem. 60:1993;1167-1170.
9. Buck K.J., Metten P., Belknap J.K., Crabbe J.C. Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice. J. Neurosci. 17:1997;3946-3955.
10. Burns R.S., LeWitt P., Ebert M.H., Pakkenberg H., Kopin I.J. The clinical syndrome of striatal dopamine deficiency; parkinsonism induced by MPTP. New Engl. J. Med. 312:1985;1418-1421.
11. Chang F.W., Wang S.D., Lu K.T., Lee E.H. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice. Brain Res. Bull. 31:1993;253-266.
12. Chung S.H., Johnson M.S. Studies on sound-induced epilepsy in mice. Proc. R. Soc. London B. 221:1984;145-168. Review; 94 refs.
13. Daly A.K., Cholerton S., Armstrong M., Idle J.R. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ. Health. Persp. 102:1994;55-61.
14. P.J. Delwaide, M. Gonce, Pathophysiology of Parkinson's signs, in: J. Jankovic, E. Tolosa (Eds.), Parkinson's Disease and Movement Disorders, Williams and Wilkins, Baltimore, 1993, pp. 77-92.
15. Di Monte D., Jewell S.A., Ekstrom G., Sandy M.S., Smith M.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137:1986;310-315.
16. Di Monte D.A., Schipper H.M., Hetts S., Langston J.W. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia. 15:1995;203-206.
17. Di Monte D.A., Schipper H.M., Hetts S., Langston J.W. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia. 15:1995;203-206.
18. Diederich N., Hilger C., Goetz C.G., Keipes M., Hentges F., Vieregg e.P., Metz H. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann. Neurol. 40:1996;463-465.
19. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 18:1996;603-606.
20. Eadie M.J. The neuropathology of Parkinson's disease. Aust. New Zealand J. Med. 1:1971;7-13. Suppl. 1.
21. Fearnley J.M., Lees A.J. Striatonigral degeneration. A clinicopathological study. Brain. 113:1990;1182-1842.
22. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv. Neurol. 60:1993;600-608.
23. Freyaldenhoven T.E., Ali S.F., Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688:1995;161-170.
24. Freyaldenhoven T.E., Cadet J.L., Ali S.F. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent. Brain Res. 735:1996;232-238.
25. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69:1997;1322-1325.
26. Gasser T., Müller-Myhsok B., Wszolek Z.K., Oehlmann R., Calne D.B., Bonifati V., Bereznai B., Fabrizio E., Vieregge P., Horstmann R.D. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18:1998;262-265.
27. German D.C., Nelson E.L., Liang C.-L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration. 5:1996;299-312.
28. Gibb W.R.G., Lee A.J. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 54:1989;388-396.
29. Giovanni A., Sonsalla P.K., Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270:1994;1008-1014.
30. Glover V., Gibb C., Sandler M. The role of MAO in MPTP toxicity - a review. J. Neural Trans. 20:1986;65-76.
31. L.I. Golbe, J.W. Langston, The etiology of Parkinson's disease: new directions for research, in: J. Jankovic, E. Tolosa (Eds.), Parkinson's Disease and Movement Disorders, Williams and Wilkins, Baltimore, 1993, pp. 93-101.
32. Hazell A.S., Itzhak Y., Liu H., Norenberg M.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J. Neurochem. 68:1997;2216-2219.
33. Heikkila R.E. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur. J. Pharmacol. 117:1985;131-133.
34. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
35. T. Hokfelt, R. Martensson, A. Bjorkland, S. Kleinau, M. Goldstein, Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain, in: A. Bjorkland, T. Hokfelt (Eds.), Handbook of Chemical Neuroanatomy, Vol. 2, Elsevier, Amsterdam, 1984, pp. 277-379.
36. Humphrey S.M., Gavin J.B., Seelye R.N., Webster V.J. Interrelationships of loss of vascular competence, ATP depletion, and decreased tissue compressibility in developing myocardial infarcts. Biochem. Med. 24:1980;6-15.
37. Ishiwata K., Ido T., Yanai K., Kawashima K., Miura Y., Monma M., Watanuki S., Takahashi T., Iwata R. Biodistribution of a positron-emitting suicide inactivator of monoamine oxidase, carbon-11 pargyline, in mice and a rabbit. J. Nucl. Med. 26:1985;630-636.
38. Johannessen J.N., Chiueh C.C., Bacon J.P., Garrick N.A., Burns R.S., Weise V.K., Kopin I.J., Parisi J.E., Markey S.P. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment. J. Neurochem. 53:1989;582-589.
39. Kilbourn M., Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur. J. Pharmacol. 307:1996;227-232.
40. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
41. B.W. Konigsmark, Methods for counting of neurons, in: W.J.H. Nauta, E.B.E. Ebbeson (Eds.), Contemporary Research Methods in Neuroanatomy, Springer, New York, 1970, pp. 315-380.
42. Kupsch A., Gerlach M., Pupeter S.C., Sautter J., Dirr A., Arnold G., Opitz W., Przuntek H., Riederer P., Oertel W.H. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 6:1995;621-625.
43. Kurth M.C., Kurth J.H. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am. J. Med. Genet. 48:1993;166-168.
44. Langston J.W. The case of the tainted heroin. The Sciences. 25:1985;34-40.
45. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chromic parkinsonism in humans due to a product of merperidine-analog synthesis. Science. 219:1983;979-980.
46. Langston J.W., Langston E.B., Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol. Scand. 100:1984;49-54.
47. Marks M.J., Stitzel J.A., Collins A.C. Genetic influences on nicotine responses. Pharmacol. Biochem. Behav. 33:1989;667-678.
48. Marsden C.D., Olanow C.W. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann. Neurol. 44:1998;S189-196. Review; 25 refs.
49. May T., Pawlik M., Rommelspacher H. [3H]harman binding experiments: II. Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat. J. Neurochem. 56:1991;500-508.
50. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.-X., Cote L.J., Stern Y. A population-based investigation of Parkinson's disease with an without dementia. Relationship to age and gender. Arch. Neurol. 49:1992;492-497.
51. G.A. Milliken, Analysis of messy data, Design of Experiments, Vol. 1, Chapman & Hall, New York, 1992.
52. Nelson E.L., Liang C.-L., Sinton C.M., German D.C. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369:1996;361-371.
53. Neystat M., Troy C.M., Lynch T., Vu T., Przedborski S. Differential display in PC12 cells exposed to MPP+. Soc. Neurosci. Abstr. 23:1997;1654.
54. Nussbaum R.L., Polymeropoulos M.H. Genetics of Parkinson's disease. Hum. Mol. Genet. 6:1997;1687-1692.
55. Pakkenberg B., Moller A., Gunderson H.J., Mouritzen Dam A., Pakkenberg H. The absolute number of nerve cells of the substantia nigra in normal subjects and patients with Parkinson's disease estimated with an unbiased steriological method. J. Neurol. Neurosurg. Psychiatry. 54:1991;30-33.
56. J. Parkinson, An Essay on Shaking Palsy, Sherwood, Neeley and Jones, London, 1817.
57. Paterson A.H. Molecular dissection of quantitative traits: progress and prospects. Genome Res. 5:1995;321-333.
58. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13:1993;4246-4253.
59. Plomin R., McClearn G.E., Gora-Maslak G., Neiderhise R.J.M. Use of recombinant inbred strains to detect quantitative trait loci associated with behavior. Behav. Genet. 21:1991;99-116.
60. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
61. Poskanzer D.C., Schwab R.S. Cohort analysis of Parkinson's syndrome:evidence for a single etiology related to subclinical infection about 1920. J. Chron. Dis. 16:1963;961-973.
62. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
63. Rajput A.H. Epidemiology of Parkinson's disease. Can. J. Neurol. Sci. 11:1984;156-159.
64. Reimer K.A., Jennings R.B., Tatum A.H. Pathobiology of acute myocardial ischemia: metabolic, functional and ultrastructural studies. Am. J. Cardiol. 52:1983;72A-81A.
65. Riachi N.J., Harik S.I. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci. 42:1988;2359-2363.
66. Sandy M.S., Armstrong M., Tanner C.M., Daly A.K., Di Monte D.A., Langston J.W., Idle J.R. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology. 47:1996;225-230.
67. SAS Institute, SAS/STAT User's Guide, Version 6, SAS Institute, NC, 1989.
68. Saura J., Nadal E., van den Berg B., Vila M., Bombi J.A., Mahy N. Localization of monoamine oxidases in human peripheral tissues. Life Sci. 59:1996;1341-1349.
69. Schapira A.H. Nuclear and mitochondrial genetics in Parkinson's disease. J. Med. Genet. 32:1995;411-414.
70. Schneider J.S., Markham C.H. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Res. 373:1986;258-267.
71. Seitelberger F. General neuropathology of degenerative processes of the nervous system. Neurosci. Res. 2:1969;253-299. Review; 30 refs.
72. Singh Y., Swanson E., Sokoloski E., Kutty R.K., Krishna G. MPTP and MPTP analogs induced cell death in cultured rat hepatocytes involving the formation of pyridinium metabolites. Toxicol. Appl. Pharmacol. 96:1988;347-359.
73. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M. Selective increase in iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982.
74. Sonsalla P.K., Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;345-354.
75. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
76. Stenstrom A., Sundstrom E., Fowler C.J. Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pharmacol. Toxicol. 64:1989;276-281.
77. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57Bl/6 mice. Comparison with three other strains of mice. Brain Res. 405:1987;26-38.
78. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P.J., Davis R.E., Parker W.D.J. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:1996;663-671.
79. Wei Q., Yeung M., Jurma O.P., Andersen J.K. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J. Neurosci. Res. 46:1996;666-673.
80. Williams R.W., Strom R.C., Goldowitz D. Natural variation in neuron number in mice is linked to a major quantitative trait locus on Chr 11. J. Neurosci. 18:1998;138-146.
81. Williams R.W., Strom R.C., Rice D.S., Goldowitz D. Genetic and environmental control of variation in retinal ganglion cell number in mice. J. Neurosci. 16:1996;7193-7205.
82. Wolman L., Roy S. The substantia nigra in Parkinsonism. J. Clin. Pathol. 22:1969;507-508.
83. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 126:1989;47-54.
84. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine. J. Biol. Chem. 268:1993;16504-16512.